ArticleSubstance abuse2021
Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.
Article in Substance abuse, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Interim opioid agonist treatment for opioid addiction: a systematic review.Harm reduction journal · 2022Pooled it
- Patient Perspectives on Offers of Buprenorphine in the Emergency Department.JAMA network open · 2026Article
- Envisioning a Humane and Accessible US Methadone Treatment System: Generating Policy and Practice Recommendations From the Liberate Methadone Movement.Substance use & addiction journal · 2026Article
- Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review.Drug and alcohol dependence reports · 2026Review
- De-implementation of inequitable methadone policy and treatment: lessons learned from COVID-19 to support a more just methadone treatment system in the United States.Frontiers in public health · 2026Review
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- Initiating Medications During Hospitalization and Strategies for Ensuring Linkage at Discharge for Patients With Opioid Use Disorder: A Scoping Review.American journal of medicine open · 2025Review
- Veterans Health System Leader and Clinician Perspectives on Expanding Access to Methadone Treatment for Opioid Use Disorder.Journal of addiction medicine · 2025Article
- Receipt of medications for opioid use disorder among rural and urban veterans health administration patients.Drug and alcohol dependence reports · 2025Article
- Evolution of the substance use landscape: Implications for contingency management.Journal of applied behavior analysis · 2025Review
- Article
- U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review.Substance use & addiction journal · 2024Article
- Methadone prescribing by addiction specialists likely to leave communities without available methadone treatment.Health affairs scholar · 2023Article
- Medications for opioid use disorder in rural primary care practices: Patient and provider experiences.Journal of substance use and addiction treatment · 2023Article
- Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.Journal of substance use and addiction treatment · 2023Review
- Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses.JAMA health forum · 2023Article
- Availability of timely methadone treatment in the United States and Canada during COVID-19: A census tract-level analysis.Drug and alcohol dependence · 2023Article
- Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.Journal of substance use and addiction treatment · 2023Article
- Article
- Article
Corrections and comments
- Erratum issuedCorrection.2022
Authors and funding
17 authors at 16 institutions in 1 country.
Funding
Abstract
In the US, methadone treatment can only be provided to patients with opioid use disorder (OUD) through federal and state-regulated opioid treatment programs (OTPs). There is a shortage of OTPs, and racial and geographic inequities exist in access to methadone treatment. The National Institute on Drug Abuse Center for Clinical Trials Network convened the Methadone Access Research Task Force to develop a research agenda to expand and create more equitable access to methadone treatment for OUD. This research agenda included mechanisms that are available within and outside the current regulations. The task force identified 6 areas where research is needed: (1) access to methadone in general medical and other outpatient settings; (2) the impact of methadone treatment setting on patient outcomes; (3) impact of treatment structure on outcomes in patients receiving methadone; (4) comparative effectiveness of different medications to treat OUD; (5) optimal educational and support structure for provision of methadone by medical providers; and (6) benefits and harms of expanded methadone access. In addition to outlining these research priorities, the task force identified important cross-cutting issues, including the impact of patient characteristics, treatment, and treatment system characteristics such as methadone formulation and dose, concurrent behavioral treatment, frequency of dispensing, urine or oral fluid testing, and methods of measuring clinical outcomes. Together, the research priorities and cross-cutting issues represent a compelling research agenda to expand access to methadone in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.